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1. Introduction 
Miniature chromosome maintenance (MCM) proteins were initially identified from 
autonomously replicating sequence in Saccharomyces cerevisiae. Mutations of some of these 
proteins such as MCM7 or MCM3 in yeast result in loss of the large chunk of yeast 
chromosomes. MCM7 cDNA encodes a 543-amino acid protein and is ubiquitously 
expressed in all tissues. Initiation of DNA replication is a complex process involving the 
concerted action of many proteins. A large body of studies indicate that MCM7 is a critical 
component of DNA replication licensing complex in the yeast and xenopus (Chong et al., 
1996; Coxon et al., 1992; Dalton and Whitbread, 1995; Kearsey et al., 1996). Some studies 
suggest that MCM4, 6 and 7 complex contains DNA helicase activity (Ishimi, 1997; You et 
al., 1999). DNA replication licensing complex is multimeric and phase specific. In the yeast, 
DNA replication licensing proteins such as MCM2-7 and several replication origin binding 
proteins such as Cdc6 and Cdt1 forms DNA replication licensing complex in G1 phase to 
enable DNA replication and to promote cell cycle entry into S phase. Such complex, 
however, dissipates in the S, G2 and M phases to prevent re-firing of DNA replication, and 
thus protect the integrity of genomes. There is little interest in MCM complex as target for 
oncongenic or tumor suppressor pathway until the links of MCM7 over-expression and 
amplification to several human malignancies were found (Brake et al., 2003; Honeycutt et 
al., 2006; Kan et al., 2009; Ren et al., 2006). 
2. MCM7 transforming oncogenic activity 
Initial implication of MCM7 involvement in human malignancies is positive 
immunostaining of MCM7 in several human malignancies, including endometrial 
carcinoma (Li et al., 2005), melanoma (Gambichler et al., 2009), esophageal adenocarcinoma 
(Kan et al., 2009), colorectal adenocarcinoma (Nishihara et al., 2008), oral squamous cell 
carcinoma (Feng et al., 2008), glioblastoma (Facoetti et al., 2006), and thyroid cancer 
(Kebebew et al., 2006). Most of these studies used MCM7 as a proliferation marker to 
compare with the existing markers such as Ki-67 or PCNA. The first study addressing the 
oncogenic role of MCM7 came from genome analysis of prostate cancer. By performing a 
genome wide copy number analysis using biotin-labeled genome DNA on Affymetrix U133 
2.0 chip (Ren et al., 2006) (figure 1). Ninety-two genes and expressed sequenced tags (ESTs) 
consistently had a two-fold or greater number of genome copies in the prostate cancer 
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specimens relative to matched blood cells (p < 0.01, using baseline analysis by Microarray 
Suite 5.0TM). To determine whether these gene amplifications were associated with increased 
expression of the same loci, mRNA expression arrays were performed with the same tumor 
samples and matched normal prostate tissue adjacent to but separate from the tumor.  Only 
five of the 92 potential amplifications had increased mRNA expression.   Using SYBR-green 
quantitative PCR and fluorescence in situ hybridization (FISH) with bacterial artificial 
chromosome containing these genes, it has been confirmed that two of these genes were 
amplified in the prostate cancer specimens. One of these genes, MCM7, located at 7q21.3 
and a component of DNA replication licensing complex, was found to be amplified 4 and 15 
fold, respectively.  
 
 
Fig. 1. Schematic diagram of genome hybridization on U133 2.0 chip. Left panel: Genome 
DNA from prostate cancer samples with matched blood were digested with Tsp509I 
restriction enzyme and ligated with an adaptor containing T7 promoter. In vitro 
transcription was then carried out to generate biotin-labeled gRNA. The gRNA was then 
fragmented and hybridized to HU133 2.0 chip for signal analysis. Right panel: Total RNA 
from matched samples of the left were reversed transcribed using T7-oligo dT (24) primer. 
After double-stranded cDNA synthesis, in vitro transcription using GTP, ATP, biotin-
labeled UTP and CTP was then performed. The resulting cRNA was then fragmented and 
hybridized to U95av2 chip.  
Subsequent validation analyses suggest that either copy number and/or protein level 
increase of MCM7 are associated with prostate cancer relapse and metastasis. To determine 
the prevalence of MCM7 amplification in prostate cancer, FISH analyses were performed on 
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74 prostate samples, including 58 cancers and 16 benign tissues (Figure 2).  Nearly half, 
(26/58, 45%) of the prostate cancers had at least a doubling in the number of genome copies 
(compared to the centromere of chromosome 7) (Table 1). Meanwhile, none of the benign 
prostate tissues demonstrated a similar amplification.  As further validation of these 
findings, SYBR-green quantitative PCR was performed on an additional 133 prostate 
samples, including 119 cancers and 14 normal tissues.  In this analysis, fifty percent (59/119) 
of the prostate cancers had at least a 2-fold increase in the MCM7/β-actin ratio relative to 
DNA from benign prostate specimens. In the most up-regulated case, the MCM7/β-actin 
ratio in the cancer sample was 16-fold greater than control levels.   
 
 
Fig. 2. MCM7 amplification and overexpression in prostate cancer. Images of fluorescence in 
situ hybridization (FISH) on normal lymphocytes, non-neoplastic prostate gland and 
prostate cancer. Chromosome 7 centromere is labeled with orange spectrum (orange), and 
MCM7 is labeled with fluorescein (green). 
Amplification of MCM7 was associated with a significantly increased rate of prostate cancer 
relapse within 5 years of radical prostatectomy (defined as a detectable PSA): 76.5% (52/68) 
patients with MCM7 amplification relapsed compared to only 12.3% (7/57) of patients 
without MCM7 amplification (p < 0.0001, log-rank test) (figure 3A).  Similar results were 
seen with MCM7 protein expression: 76.3% patients with ≥ 2+ MCM7 expression 
experienced a recurrence within 5 years after radical prostatectomy compared with only 
26.5% patients with weak MCM7 expression (p < 0.006) (figure 3B).  The combination of 
MCM7 amplification and overexpression generated additional improvement in separating 
the two groups (Figure 3C).  
Eleven clones of DU145 transfected with a constitutive MCM7 cDNA overexpression vector 
were characterized by Western blot analysis, and two with high MCM7 expression were 
chosen for subsequent analysis.  Over a 6-h experimental period DU145 pCMV-MCM7 
clones had twice the number of cells enter S phase (figure 3B), with cell proliferation being 
50% faster than vector only controls (figure 3C).  DU145 pCMV-MCM7 clones had a 2-fold 
higher level of invasiveness in Matrigel transmigration analysis compared to vector-only 
controls.  In vivo, DU145 pCMV-MCM7 xenograft tumors were twelve times larger than 
vector-only control tumors, 2.58 cm3 versus 0.22 cm3, respectively (p < 0.0001), with a 50% 
mortality within 6 weeks of innoculation (p = 0.0063).  These findings are consistent with the 
clinical findings that increased MCM7 expression is associated with higher rates of local 
tumor invasion. 
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95T 7 T3a 6.67 Y 
72T 7 T3a 6.42 Y 
54T 9 T3b 6.1 Y 
45T 6 T2b 5.49 Y 
139T 8 T2b 4.2 Y 
69T 6 T3a 4.15 Y 
5T 7 T2b 3.97 Y 
85T 7 T2b 3.77 Y 
48T 8 T3a 3.5 Y 
4T 9 T3b 3.3 Y 
101T 6 T3a 3.11 Y 
107T 6 T3a 3.11 Y 
2213T 6 T3a 3.06 Y 
42T 7 T3a 2.69 Y 
214T 6 T3a 2.66 Y 
3T 9 T3b 2.52 Y 
2T 7 T3a 2.49 Y 
147T 6 T3a 2.46 Y 
68T 6 T2b 2.1 Y 
22T 6 T3a 1.86 Y 
7T 7 T3a 1.62 Y 
93T 9 T3b 1.52 Y 
6T 6 T2b 1.5 Y 
641T 6 T2b 1.1 Y 
56T 6 T2b 0.95 Y 
39T 7 T3a 0.84 Y 
40T 6 T3a 5.76 N 
75T 6 T2b 5.55 N 
911T 6 T3a 4.48 N 
46T 7 T3a 4.47 N 
83T 7 T2b 1.94 N 
99T 8 T3a 1.82 N 
13T 7 T2b 1.74 N 
67T 9 T3b 1.64 N 
1127T 6 T3a 1.58 N 
M35 6 T2b 1.55 N 
26T 6 T2a 1.54 N 
11T 7 T2b 1.54 N 
194T 6 T2b 1.37 N 
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82T 7 T3a 1.24 N 
55T 6 T2b 1.18 N 
91T 7 T2b 1.14 N 
94T 7 T3a 1.13 N 
96T 6 T2a 0.97 N 
941T 6 T2b 2.17 U 
M33 8 T3b 2.13 U 
M29 7 T3b 2.05 U 
217T 7 T3a 1.96 U 
121T 6 T2b 1.86 U 
M21 6 T2b 1.68 U 
M24 6 T2b 1.64 U 
853T 6 T2b 1.49 U 
M28 8 T3b 1.39 U 
998T 6 T2b 1.29 U 
M36 7 T2b 1.14 U 
M31 7 T3a 1.11 U 
828T 6 T2b 1 U 
M23 7 T2b 0.94 U 
M2 Normal Prostate 1.2 N/A 
A4 Normal Prostate 1.01 N/A 
M4 Normal Prostate 0.9 N/A 
P28 Normal Prostate 1.2 N/A 
P91 Normal Prostate 0.89 N/A 
P93 Normal Prostate 0.95 N/A 
U-2 Normal Prostate 1.3 N/A 
D-41 Normal Prostate 0.8 N/A 
U-4 Normal Prostate 1.2 N/A 
9 Normal Prostate 1 N/A 
19 Normal Prostate 1.09 N/A 
99 Normal Prostate 0.93 N/A 
l1 Normal Prostate 1.02 N/A 
l2 Normal Prostate 1.08 N/A 
l3 Normal Prostate 1.03 N/A 
l4 Normal Prostate 1.05 N/A 
 
 
Y-yes; N-No; U-undetermined due to lack of follow-up; N/A-not applicable. 
*Determined by PSA relapse or physical evidences of metastasis within 5 years after prostatectomy. 
Table 1. FISH analysis of MCM7 amplification in primary prostate cancer 
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Fig. 3. MCM7 amplification and overexpression associated with prostate cancer relapse. A. 
Kaplan curves of samples from patients with clinical follow-up for 5-year period. The 
samples were divided by presence (Y) or absence (N) of MCM7 amplification based on FISH 
and/or quantitative PCR. Ratios of MCM7/Centromere or MCM7/β-actin >2 are considered 
an increase of MCM7 DNA. B. Kaplan curves of samples from patients with clinical follow-
up for 5-year period. The samples were divided by MCM7 expression scores: scoring > 2+ or 
< 1.C. Kaplan curves of samples from patients with clinical follow-up for 5-year period. The 
samples were divided by presence (Y) or absence (N) of MCM7 amplification and MCM7 
overexpression. 
Amplification of MCM7 was also found in esophageal carcinoma (Kan et al., 2009). The 
magnitude of MCM7 amplification correlates with the expression of MCM7, tumor grades 
and aggressiveness of the esophageal cancer (Kan et al., 2009). It is presumed that 
amplification of MCM7 is the driving force of MCM7 over-expression in primary human 
malignancies. When MCM7 was transgened in basal cells of skin of mice utilizing keratin 
promoter, the animals developed squamous cell carcinoma upon DMBA/TPA challenge 
versus complete negative results from the WT controls (Honeycutt et al., 2006). However, 
MCM7 does not play an initiator role in cancer development because organ specific MCM7 
transgene mice develop no spontaneous cancer either in skin nor prostate model (Honeycutt 
et al., 2006; Poliseno et al.). The inability of MCM7 expression alone to initiate carcinogenesis 
could result from other negative feedback mechanisms that neutralize MCM DNA 
replication licensing in the cell, such as Rb or ILK signaling discussed later. Even though 
MCM7’s transforming activity is clearly observed, strictly speaking, it does not fall into the 
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category of a typical proto-oncogene because it does not have a viral counterpart nor 
sequence mutations that render its oncogenic potential. MCM7 probably falls into the 
broadly defined oncogene category whose gain of oncogenic function is generated by 
epigenome or chromosomal numerical alterations.  
3. MCM7 as target of oncogenic or tumor suppressor signaling pathways 
The first significant signaling pathway targeting MCM7 was found by yeast two-hybrid 
screening analysis where the N-terminus of Rb bait probe binds with MCM7 (Sterner et al., 
1998). Additional analysis suggests that other Rb homologues p107 and p130 also bind with 
MCM7 (Sterner et al., 1998). In vitro analysis indicates that the binding of MCM7 and Rb 
inhibits DNA replication. However, the biological significance of such interaction was not 
elucidated until 11 years later that interaction of Rb-MCM7 is essential for TGFβ induced 
blockade of entry into S phase (Mukherjee et al.). These studies suggest that MCM7 could be 
the main target of Rb in controlling cycle S phase check point (figure 4). This is because 
over-expression of MCM7 can reverse Rb inhibition effect, and peptide that interferes with 
MCM7/Rb binding but not other activity of Rb also reverses the Rb check point blockade. 
Another salient example of MCM7 as a target of a signaling pathway is androgen receptor 
signaling. It is well known that androgen receptor regulates cell growth and proliferation. 
However, most of the studies have been focusing on gene expression regulation which may 
play secondary role in controlling cell cycle progression. It was found later that AR interacts 
with MCM7 directly, and inactivates or activates MCM DNA replication licensing 
depending on the nature of ligands or their concentrations (Shi et al., 2008). Mutation of 
MCM7 that abrogates its interaction with androgen receptor but not its DNA replication 
licensing activity eliminates the pleiotrophic effect of testosterone. Furthermore, androgen 
receptor mutant that does not bind with MCM7 can translocate into nucleus upon androgen 
stimulation but fails to induce cell proliferation or to enhance transcription of androgen 
dependent genes. It appears that both DNA replication activity and transcription activity of 
AR is dependent on its binding with MCM7. It is likely that AR serves as a co-replication 
factor that directs the MCM complex DNA replication licensing through its interaction with 
MCM7 (figure 4). One surprising finding in the analysis is that MCM7 also serves as a co-
transcription factor for AR. There are several well read studies showing that transcription 
activity enhances DNA replication, and that transcription activity is dependent on DNA 
replication in eukaryotic cells (Marahrens and Stillman, 1992; Veldman et al., 1985). It 
remains to be seen whether MCM7 dependent transcription activity holds truth with other 
MCM7 interacting transcription factors. The MCM7 dependency of androgen receptor 
transcription activity suggests that androgen dependent gene expression could only occur in 
actively proliferating cells, since MCM7 is excluded from the nucleus during S, G2 and M 
phases, and it only re-enters the nucleus in G1 phase.  
MCM7 also plays some critical role in mediating the function of cell membrane receptor. 
This is demonstrated in its interaction with integrin linked kinase (figure 4). It appears that 
MCM7 is a substrate of integrin linked kinase. The binding and phosphorylation of MCM7 
N-terminus by integrin linked kinase reduce the binding of MCM7 with other DNA 
replication licensing factors, and lead to slow-down of cell growth (Han et al., 2010). The 
phosphorylation of MCM7 by integrin linked kinase proves to be a critical link to the tumor 
suppressor activity of integrin α7. Dominant negative mutant of integrin linked kinase 
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interrupts the integrin linked kinase/MCM7 interaction, and partly blocks the tumor 
suppression activity of integrin α7. MCM7 mutant that lacks the integrin linked kinase 
binding motif operates DNA replication licensing similar to that of wild type but is 
unresponsive to integrin α7 signaling. These findings suggest that MCM7 could be the end 
target of many oncogenic or tumor suppressing signaling pathways. Depending on the 
nature of these interactions or modification of MCM7, it may lead to increased or decreased 
DNA replication licensing activity of MCM complex, and guides the cells into either higher 
level of proliferation or cell growth arrest.  
 
 
Fig. 4. Diagram of MCM7 oncogenic signaling. Fifteen exons and miR106b-25 oncogenic 
miRNA cluster of MCM7 genome were transcribed into MCM7 mRNA and miRNA 106b, 93 
and 25. Two prong pathways were directed at promoting DNA replication: Degradation of 
critical tumor suppressor genes p21 and pTEN mRNA by miR106b-25 cluster, and increase 
of DNA replication licensing by MCM7 protein. Androgen receptor (AR) promotes DNA 
replication by enhancing MCM7 replication licensing activity. Integrin α7 inhibits DNA 
replication through inhibition of MCM7 activity.  
4. Transforming miRNA cluster in MCM7 genome 
A unique feature of MCM7 genome is that it contains an intronic miRNA miR-106b-25 
cluster in intron 13, which includes miR-106b, miR93 and miR-25. miR-25 is highly 
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homologous to miR-32, a onco-miRNA, while miR-106b and miR-93 belong to the family of 
miR-17. All three members of miR-106b-25 cluster are abundantly expressed in most of the 
prostate cancer cell lines. Similar to their host gene MCM7, amplification and up-regulation 
of all members of miR-106b-25 cluster are found in several human malignancies including 
esophageal and prostate cancers (Ambs et al., 2008; Kan et al., 2009; Petrocca et al., 2008a; 
Poliseno et al., ; Sikand et al., 2009). These miRNAs target multiple tumor suppressor genes, 
and shut down their expression levels (figure 4). One of the most notable examples is pTEN 
gene expression. miR-25 and miR-93 expression decrease pTEN protein levels, and result in 
activation of AKt pathway (Poliseno et al.). The expression of miR106-25 cluster increase 
tumorigenesis in both anchorage-independent assay and xenografted tumors in animal 
model. The mice with knock-in prostate specific MCM7 and miR-106-25 cluster develop 
cancer like dysplasia in mice, while mice with pure MCM7 knock in do not seem to develop 
dysplasia without carcinogen challenge. One may interpret such observation as miR-106-25 
cluster function as tumor initiator by knocking down pTEN in mice, while over-expression 
of MCM7 serves as a mechanism for the development of invasive phenotype. miR-106b-25 
cluster appears more versatile than knocking down just one tumor suppressor gene. Several 
studies suggest that miR-106 and miR-25 target p21, Bim and E2F1 (Ambs et al., 2008; Kan et 
al., 2009; Petrocca et al., 2008a; Petrocca et al., 2008b). These targets and their relationship 
have been clearly demonstrated in prostate cancer, esophageal adenocarcinoma and gastric 
cancer. Inhibition of E2F1 by miR-106b and miR-93 in gastric cancer cell lines partially 
blocks TGFβ induced apoptosis (Petrocca et al., 2008b). Interestingly, E2F1 is a strong 
stimulator of MCM7 locus transcription. As a result, a negative feedback loop of 
MCM7/miR-106b-25 is formed. Such feedback loop may serve to limit the excessive cell 
death induced by TGFβ in physiological condition, and thus achieves a balance of cell 
growth and cell death. In the event of malignancies, amplification of MCM7 locus may 
bypass such negative feedback loop, and tips the balance to cell survival. Targeting on 
p21waf and bim by miR-106b and miR-25 were demonstrated in both esophageal and 
prostate cancers. Application of inhibitors of miR-106, miR-93 or miR-25 inhibits 
tumorigenesis both in vitro and in vivo. With these targets that all appear critical for the 
oncogenic activity of miR-106b-25 cluster, it is not easy to analyze the contribution of each of 
these pathways to carcinogenesis since there is a lack of experiments to block off each of the 
pathways to offset the oncogenic activity of miR-106b-25 cluster. Generally speaking, miR-
25/93-pTEN pathway is compelling because of the inverse correlation of pTEN expression 
and miR-106b-25 miRNA levels in primary and mouse tumor samples, the animal model 
initiating prostate cancer with MCM7/miR-106b-25 cluster transgene showing clear down-
regulation of pTEN expression and concomitant increased level of miR-106b-25 cluster 
expression, and consequent Akt pathway activation. It would be of interest to see how much 
oncogenic phenotype will be reversed if these animals are transgened with pTEN, or p21 or 
BIM or E2F1 gene construct lacking the miR-106b-25 target sequences in their 3’ 
untranslated regions.  
5. Potential therapeutic target 
MCM7 is essential for any cell that undergoes proliferation. This poses a dilemma for 
MCM7 gene targeted therapy. Nevertheless, a report indicates that shRNA targeting MCM7 
in xenografted PC3 and DU145 tumors in mice dramatically reduces tumor volume, rate of 
metastasis and fatality (Shi et al., 2010). The drawback of this analysis is that the shRNA 
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target may not recognize the MCM7 sequence from mice since the target sequence is 
intended for human MCM7. Nevertheless, the study is a proof of principle that MCM7 
kncokdown is a potential effective approach in combating prostate cancer, particularly those 
with MCM7 amplification and over-expression. In light of double oncogenic effect of MCM7 
genome cluster, it may be more effective if a shRNA is designed to neutralize the effect of 
miR-106b, miR-93 and miR-25 onco-miRNA. This can be accomplished with large dosage of 
morpholino oligonucleotide specific for these onco-miRNAs. These RNAse resistent 
oligonucleotides have a clear advantage over genome approach that it will not interfere with 
the genome structure of a cell but have long lasting presence once they are taken. 
Furthermore, there is no evidence suggesting that knocking down of these miRNAs 
adversely affects the survival of normal cells.  
6. Abreviation  
M7-MCM7; M6-MCM6; M5-MCM5; M4-MCM4; M3-MCM3; M2-MCM2; ITGA7- Integrin 
α7; ILK-integrin linked kinase; AR-androgen receptor; ORC-origin recognition complex. 
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includes the latest on mechanisms of replication in prokaryotes. The association between genome replication
and transcription is also addressed. We hope that readers will find this book interesting, helpful and inspiring.
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